- Home
- FNKO vs PLX Comparison
FNKO vs PLX Comparison
Compare FNKO & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FNKO | PLX |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.7M | 230.0M |
| IPO Year | 2017 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FNKO | PLX |
|---|---|---|
| Price | $4.72 | $3.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $5.50 | ★ $12.00 |
| AVG Volume (30 Days) | 936.6K | ★ 1.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,049,850,000.00 | $53,399,000.00 |
| Revenue This Year | N/A | $9.67 |
| Revenue Next Year | $10.54 | $23.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.22 | $1.34 |
| 52 Week High | $11.50 | $3.19 |
Technical Indicators
Market Signals| Indicator | FNKO | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 58.00 | 62.71 |
| Support Level | $2.80 | $1.39 |
| Resistance Level | $5.52 | $3.03 |
| Average True Range (ATR) | 0.39 | 0.16 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 56.60 | 68.18 |
Price Performance
Historical ComparisonAbout FNKO Funko Inc.
Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.